Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Table 1

Demographic and clinical characteristics of the study population.

Characteristics	PH patients; ()
Age, years	50.4 ± 13.7
Gender, (%)
Female	37 (75.5)
Male	12 (24.5)
Marital status, (%)
Single	11 (22.4)
Married/divorced/widowed	38 (77.6)
Working status, (%)
Full-time	15 (34.7)
Homemaker	9 (18.4)
Retired	23 (46.9)
Disease duration, months	57.1 ± 58.8
PH aetiology, (%)
PAH and others	37 (75.5)
CTEPH	12 (24.5)
Comorbidities, (%)
Yes	28 (57.1)
No	21 (42.9)
WHO Functional class, (%)
I/II	34 (69.4)
III/IV	15 (30.6)
6MWD, meters	428.0 ± 105.8
Borg dyspnea	2.2 ± 2.6
HR_Bas, bpm	78.2 ± 11.6
HR_Max, bpm	107.9 ± 19.1
SBP, mmHg	113.4 ± 17.7
DBP, mmHg	68.2 ± 13.6
O2Sat_Bas, mmHg	94.0 ± 3.4
O2Sat_Min, mmHg	80.5 ± 15.1
NT-proBNP, pg/mL	684.6 ± 908.4
RAP, mmHg	7.1 ± 4.6
mPAP, mmHg	44.8 ± 18.2
PAOP, mmHg	9.8 ± 4.1
CI, L/min/m^2	3.1 ± 0.9
PVR, Wood units	7.0 ± 4.3
Diuretics, (%)
Yes	29 (59.2)
No	20 (40.8)
Oral anticoagulants, (%)
Yes	24 (49.0)
No	25 (51.0)
Calcium channel blockers, (%)
Yes	5 (10.2)
No	44 (89.8)
Oxygen therapy, (%)
Yes	20 (40.9)
No	29 (59.1)
PH specific therapy, (%)
Monotherapy	23 (46.9)
Combination therapy	20 (40.8)
No therapy	6 (12.2)
PH specific therapy route, (%)
Oral	36 (73.5)
Parenteral	7 (14.3)

Data displayed as mean ± SD, except when otherwise indicated; 6MWD: 6-minute walk distance; NT-proBNP: N-terminal pro-brain natriuretic peptide; Borg: Borg dyspnea score; CI: cardiac index; CTEPH: chronic thromboembolic pulmonary hypertension; DBP: diastolic blood pressure; HR_Bas: baseline heart rate; HR_Max: maximum heart rate; mPAP: mean pulmonary arterial pressure; PAH: pulmonary arterial hypertension; PAOP: pulmonary artery occlusion pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; O2Sat_min: minimum oxygen saturation; O2Sat_bas: baseline oxygen saturation; SBP: systolic blood pressure. therapy: CTEPH patients waiting for surgical treatment ; Porto-pulmonary hypertension waiting for liver transplantation . Low risk congenital heart disease , and idiopathic PAH before specific therapeutic introduction .